Parker E, Van Heek M, Stamford A (April 2002). "Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status". European Journal of Pharmacology. 440 (2–3): 173–87.
doi:
10.1016/S0014-2999(02)01427-9.
PMID12007534.
Sheriff S, F Qureshy A, T Chance W, Kasckow JW, Balasubramaniam A (January 2002). "Predominant role by CaM kinase in NPY Y(1) receptor signaling: involvement of CREB [corrected]". Peptides. 23 (1): 87–96.
doi:
10.1016/S0196-9781(01)00583-6.
PMID11814622.
S2CID54419749.
Uddman R, Möller S, Nilsson T, Nyström S, Ekstrand J, Edvinsson L (May 2002). "Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues". Peptides. 23 (5): 927–34.
doi:
10.1016/S0196-9781(02)00003-7.
PMID12084524.
S2CID31244551.
Cantó Soler MV, Gallo JE, Dodds RA, Hökfelt T, Villar MJ, Suburo AM (September 2002). "Y1 receptor of neuropeptide Y as a glial marker in proliferative vitreoretinopathy and diseased human retina". Glia. 39 (3): 320–4.
doi:
10.1002/glia.10107.
PMID12203398.
S2CID41750584.
Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR (July 2003). "The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 147–56.
doi:
10.1124/jpet.103.051227.
PMID12665544.
S2CID40163065.
"Neuropeptide Y Receptors: Y1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from
the original on 2016-03-03. Retrieved 2008-12-09.
Overview of all the structural information available in the
PDB for
UniProt: P25929 (Neuropeptide Y receptor type 1) at the
PDBe-KB.